exsulin corporation is developing a novel breakthrough drug aimed at the underlying cause of Type 1 and Type 2 diabetes (T1DM and T2DM). The proprietary drug, branded as exsulin™, uses a synthetic version of naturally-occurring peptide that induces regeneration of normal functioning pancreatic islet cells – islets contain the insulin-producing beta-cells and the glucagon-producing alpha cells which are both important to normal glycemic control. Regeneration of islets could turn back the clock on insulin-dependent diabetes (both Type 1 and Type 2) and help reduce or eliminate the need for injected insulin, a difficult therapy that carries a risk of serious hypoglycemia. C-peptide is a substance the pancreas releases into the bloodstream in equal amounts to insulin and a simple blood test of C-peptide levels shows how much insulin the body is making. Data demonstrate that even relatively modest levels of insulin secretion as measured by C-peptide will result in clinically meaningful benefits including easier and better glycemic control and fewer end-organ complications, especially retinopathy.

exsulin is aimed at meeting an urgent need reflected by the seriousness of insulin-dependent diabetes. Currently, there is no cure or alternative treatment for insulin-dependent diabetes. Even though insulin therapies continue to improve, it remains difficult to achieve normal glycemic control in type 1 diabetes, especially long term, with insulin replacement therapy alone. The associated risks of hypoglycemia and end-organ diabetic complications remain. Retention of beta-cell function in patients with type 1 diabetes is known to result in improved glycemic control and reduced hypoglycemia, retinopathy, and nephropathy. Rates of severe hypoglycemia and diabetic complications ultimately will be improved by therapies that are effective at preserving or regenerating beta-cell function.

The success of a drug that could markedly mitigate and even reverse the effects of insulin loss would be a major advance in the history of diabetes treatment. Phase II clinical trials of exsulin are currently underway at Mayo Clinic and McGill University Hospital Centre.

exsulin corporation is committed to working closely with patients not only as participants in its clinical trials but as a major source of advice, support, and advocacy. The company is pledged to providing timely, accurate updates about progress with exsulin development.

Common Terms: (from American Diabetes Association)

C-peptide (see-peptide)
"Connecting peptide," a substance the pancreas releases into the bloodstream in equal amounts to insulin. A test of C-peptide levels shows how much insulin the body is making.

glucagon (GLOO-kah-gahn)
a hormone produced by the alpha cells in the pancreas. It raises blood glucose. An injectable form of glucagon, available by prescription, may be used to treat severe hypoglycemia.

honeymoon phase
Some people with type 1 diabetes experience a brief remission called the "honeymoon period." During this time their pancreas may still secrete some insulin. Over time, this secretion stops and as this happens, the child will require more insulin from injections. The honeymoon period can last weeks, months, or even up to a year or more.

a hormone that helps the body use glucose for energy. The beta cells of the pancreas make insulin. When the body cannot make enough insulin, it is taken by injection or through use of an insulin pump.

hypoglycemia (hy-po-gly-SEE-mee-uh)
a condition that occurs when one's blood glucose is lower than normal, usually less than 70 mg/dL. Signs include hunger, nervousness, shakiness, perspiration, dizziness or light-headedness, sleepiness, and confusion. If left untreated, hypoglycemia may lead to unconsciousness. Hypoglycemia is treated by consuming a carbohydrate-rich food such as a glucose tablet or juice. It may also be treated with an injection of glucagon if the person is unconscious or unable to swallow. Also called an insulin reaction.

groups of cells located in the pancreas that make hormones that help the body break down and use food. For example, alpha cells make glucagon and beta cells make insulin. Also called islets of Langerhans (LANG-er-hahns).